Skip to content
value.today

Ambu A/S vs NovoCure Limited

Add a company

Market value, revenue, profit, valuation and financial strength side by side, each from the company's own filings or market data, with its date.

In short

  • Ambu A/S is the larger company by market value: $3.2 B against $1.5 B for NovoCure Limited, 2.1 times as much (market caps of Aug 1, 2026 for Ambu A/S and Oct 30, 2026 for NovoCure Limited). Ambu A/S's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.
  • Ambu A/S had more revenue: $657 M in the year to September 2022 against $655 M for NovoCure Limited in the year to December 2025.
  • Ambu A/S made a net profit of $14 M, while NovoCure Limited made a net loss of $136 M.
  • Ambu A/S keeps more of each dollar of sales: a net margin of 2.1% against -20.8% for NovoCure Limited.
  • Ambu A/S employs more people: 3,500 against 1,023 at NovoCure Limited. Each employee brings in about $187,714 of revenue at Ambu A/S and $640,616 at NovoCure Limited.

Market value, the same start = 100

From Jan 2020: how each one's value moved, whatever its size.

0651291942592020202120222023202420252026Ambu A/S 76NovoCure Limited 19

Revenue by fiscal year

US$ billions, as reported in each year's annual results.

$0B$0B$0B$0B$1B201720182019202020212022202320242025NovoCure Limited $1B

Side by side

Side-by-side comparison; ▲ marks the best value of a measure where higher or lower is better
MeasureAmbu A/S
AMBU-B.CO · #4,870 in the world
NovoCure Limited
NVCR · #7,428 in the world
Profile
Country🇩🇰 Denmark🇬🇧 UK
SectorHealthcareHealthcare
IndustryMedical InstrumentsMedical Instruments
Founded19372000
Size
Market cap$3.2 B$1.5 B
Revenue$657 M$655 M
Net income$14 M▲ best$-136 M
Employees3,5001,023
Valuation
P/E ratio226×—
Price to sales4.8×2.1×
Price to book3.4×4.5×
Free cash flow yield—-4.9%
Profitability
Gross margin—74.5%
Operating margin—-23.5%
Net margin—-20.8%
Return on equity—-38.9%
Growth
Revenue growth—8.3%
Revenue growth, 3 years a year—6.8%
Financial strength
Debt to equity—0.6×
Interest cover—-6.9×
Cash
Free cash flow margin—-11.6%
Strength scores
Piotroski F-score—3 of 9
Altman Z-score zone—distress
Data as ofMarket cap Aug 2026; ratios FY2025Market cap Oct 2026; ratios FY2025

▲ marks the better of the two where higher or lower is better; size and valuation multiples are marked for neither

Questions and answers#

Which is bigger, Ambu A/S or NovoCure Limited?

Ambu A/S is the larger company by market value: $3.2 B against $1.5 B for NovoCure Limited, 2.1 times as much (market caps of Aug 1, 2026 for Ambu A/S and Oct 30, 2026 for NovoCure Limited). Ambu A/S's value is the last on file, from Aug 1, 2026: no market-data feed is connected for its exchange yet.

Which makes more money, Ambu A/S or NovoCure Limited?

Ambu A/S had more revenue: $657 M in the year to September 2022 against $655 M for NovoCure Limited in the year to December 2025. Ambu A/S made a net profit of $14 M, while NovoCure Limited made a net loss of $136 M.

Which is more profitable, Ambu A/S or NovoCure Limited?

Ambu A/S keeps more of each dollar of sales: a net margin of 2.1% against -20.8% for NovoCure Limited.

Which has more employees, Ambu A/S or NovoCure Limited?

Ambu A/S employs more people: 3,500 against 1,023 at NovoCure Limited. Each employee brings in about $187,714 of revenue at Ambu A/S and $640,616 at NovoCure Limited.

Sources#

Every figure on this page comes from these, with the date shown next to it.